Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

ClinicalTrials.gov ID: NCT02616601

Public ClinicalTrials.gov record NCT02616601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Fluorouracil Cream, 0.5% and Carac® (Fluorouracil) Cream, 0.5% in Subjects With Actinic Keratoses

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.

Study identification

NCT ID
NCT02616601
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
422 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 26, 2015
Primary completion
Sep 16, 2015
Completion
Sep 16, 2015
Last update posted
Jul 16, 2019

2015

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Investigative Site 2 Fremont California
Investigative Site 16 Los Angeles California
Investigative Site 17 San Diego California
Investigative Site 4 Denver Colorado
Investigative Site 10 Newnan Georgia
Investigative Site 5 Boise Idaho
Investigative Site 1 Arlington Heights Illinois
Investigative Site 11 Buffalo Grove Illinois
Investigative Site 3 Carmel Indiana
Investigative Site 9 Plainfield Indiana
Investigative Site 6 South Bend Indiana
Investigative Site 8 Clinton Township Michigan
Investigative Site 13 Warren Michigan
Investigative Site 12 Fridley Minnesota
Investigative Site 15 Albuquerque New Mexico
Investigative Site 7 High Point North Carolina
Investigative Site 14 Philadelphia Pennsylvania

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02616601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02616601 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →